Journal ArticleDOI
A systematic review of salivary gland hypofunction and xerostomia induced by cancer therapies: management strategies and economic impact
Siri Beier Jensen,Anne Marie Lynge Pedersen,Arjan Vissink,Elo Andersen,Carlton G. Brown,Andrew Davies,J. Dutilh,Janet S. Fulton,Ljiljana Janković,Nilza Nelly Fontana Lopes,A. L. S. Mello,L. V. Muniz,C. A. Murdoch-Kinch,Raj G. Nair,Joel J. Napeñas,A. Nogueira-Rodrigues,Deborah P. Saunders,B. Stirling,I. von Bültzingslöwen,Dianna Weikel,Linda S. Elting,Fred K. L. Spijkervet,Michael T. Brennan,Salivary Gland Hypofunction,Xerostomia Section +24 more
Reads0
Chats0
TLDR
There is evidence that salivary gland hypofunction and xerostomia induced by cancer therapies can be prevented or symptoms be minimized to some degree, depending on the type of cancer treatment.Abstract:
This systematic review aimed to assess the literature for management strategies and economic impact of salivary gland hypofunction and xerostomia induced by cancer therapies and to determine the quality of evidence-based management recommendations. The electronic databases of MEDLINE/PubMed and EMBASE were searched for articles published in English since the 1989 NIH Development Consensus Conference on the Oral Complications of Cancer Therapies until 2008 inclusive. For each article, two independent reviewers extracted information regarding study design, study population, interventions, outcome measures, results, and conclusions. Seventy-two interventional studies met the inclusion criteria. In addition, 49 intensity-modulated radiation therapy (IMRT) studies were included as a management strategy aiming for less salivary gland damage. Management guideline recommendations were drawn up for IMRT, amifostine, muscarinic agonist stimulation, oral mucosal lubricants, acupuncture, and submandibular gland transfer. There is evidence that salivary gland hypofunction and xerostomia induced by cancer therapies can be prevented or symptoms be minimized to some degree, depending on the type of cancer treatment. Management guideline recommendations are provided for IMRT, amifostine, muscarinic agonist stimulation, oral mucosal lubricants, acupuncture, and submandibular gland transfer. Fields of sparse literature identified included effects of gustatory and masticatory stimulation, specific oral mucosal lubricant formulas, submandibular gland transfer, acupuncture, hyperbaric oxygen treatment, management strategies in pediatric cancer populations, and the economic consequences of salivary gland hypofunction and xerostomia.read more
Citations
More filters
Journal ArticleDOI
Comparison of Prostate-Specific Membrane Antigen Expression Levels in Human Salivary Glands to Non-Human Primates and Rodents
Jyoti Roy,Blake M. Warner,Falguni Basuli,Xiang Zhang,Karen Wong,Thomas Pranzatelli,Anita T. Ton,John A. Chiorini,Peter L. Choyke,Frank I. Lin,Elaine M. Jagoda +10 more
TL;DR: The results suggest that mice are relatively a better small animal preclinical model than rats for PSMA salivary gland studies and suggest that PSMA-RNT-related xerostomia could be clinically useful.
Journal ArticleDOI
New pharmacotherapy options for chemotherapy-induced alimentary mucositis
TL;DR: This critical review will provide an overview of emerging pharmacotherapies for the treatment of alimentary mucositis following chemotherapy with particular emphasis on studies published in the last 2 years.
Journal ArticleDOI
Clinical features and preventive therapies of radiation-induced xerostomia in head and neck cancer patient: a literature review
TL;DR: Salivary gland cytoprotectants (amifostine), muscarinic agonist stimulation (pilocarpine and bethanechol), salivary glands-sparing radiation technique (intensity-modulated radiotherapy- IMRT), surgical relocation of the submandibular gland, intraoral stent and stem cell transplantation are promising techniques that are discussed in this study.
Journal ArticleDOI
Incidence of salivary side effects after radioiodine treatment using a new specifically-designed questionnaire
Eric Moreddu,Karine Baumstarck-Barrau,Sophie Gabriel,Nicolas Fakhry,Frederic Sebag,Olivier Mundler,Cyrille Chossegros,David Taïeb +7 more
TL;DR: The number of side effects of radioiodine treatment in a large group of patients with a newly-established diagnosis of thyroid cancer has been highlighted and corroborates previous observations.
Journal ArticleDOI
Functional Swallowing Outcomes in Nasopharyngeal Cancer Treated with IMRT at 6 to 42 months Post-Radiotherapy
Margaret Patterson,Rowena Brain,Ronald Y. Chin,Ronald Y. Chin,David Veivers,David Veivers,Michael Back,Michael Back,Andrew Wignall,Thomas Eade,Thomas Eade +10 more
TL;DR: While all patients returned to a fully oral diet, there was ongoing swallow dysfunction characterised by bolus residue and delay, but no aspiration, and the cohort lacked the morbidity experienced by cohorts reported in earlier studies, potentially due to the use of IMRT.
References
More filters
Journal ArticleDOI
Dose, volume, and function relationships in parotid salivary glands following conformal and intensity-modulated irradiation of head and neck cancer
TL;DR: Dose/volume/function relationships in the parotid glands are characterized by dose and volume thresholds, steep dose/response relationships when the thresholds are reached, and a maximal volume dependence parameter in the NTCP model.
Journal ArticleDOI
Phase III Randomized Trial of Amifostine as a Radioprotector in Head and Neck Cancer
David M. Brizel,Todd H. Wasserman,Michael Henke,Vratislav Strnad,Volkar Rudat,Alain Monnier,François Eschwege,Jay Zhang,Lesley Russell,Wolfgang Oster,Rolf Sauer +10 more
TL;DR: With and without amifostine, 2-year local-regional control, disease-free survival, and overall survival were 58% versus 63, 53% versus 57%, and 71% versus 66%, respectively, while Antitumor treatment efficacy was preserved.
Journal ArticleDOI
Xerostomia and its predictors following parotid-sparing irradiation of head-and-neck cancer
Avraham Eisbruch,Hyungjin Myra Kim,Jeffrey E. Terrell,Jeffrey E. Terrell,Lon H. Marsh,Laura A. Dawson,Jonathan A. Ship +6 more
TL;DR: An improvement over time in xerostomia, occurring in tandem with rising salivary production from the spared major Salivary glands, suggests a long-term clinical benefit from their sparing.
Journal ArticleDOI
Xerostomia and quality of life after intensity-modulated radiotherapy vs. conventional radiotherapy for early-stage nasopharyngeal carcinoma: initial report on a randomized controlled clinical trial.
Edmond H.N. Pow,Dora L.W. Kwong,Anne S. McMillan,May C. M. Wong,Jonathan S.T. Sham,Lucullus H.T. Leung,W. Keung Leung +6 more
TL;DR: IMRT was significantly better than CRT in terms of parotid sparing and improved QoL for early-stage disease and support the case for assessment of health-relatedQoL in relation to head-and-neck cancer using a site-specific approach.
Journal ArticleDOI
Prospective Randomized Study of Intensity-Modulated Radiotherapy on Salivary Gland Function in Early-Stage Nasopharyngeal Carcinoma Patients
Michael K.M. Kam,Sing Fai Leung,Benny Zee,Ricky M. C. Chau,Joyce J. S. Suen,Frankie Mo,Maria Lai,Rosalie Ho,Kin Yin Cheung,Brian K.H. Yu,Samuel K.W. Chiu,Peter H.K. Choi,Peter M.L. Teo,Wing Hong Kwan,Anthony T.C. Chan +14 more
TL;DR: IMRT is superior to 2DRT in preserving parotid function and results in less severe delayed xerostomia in the treatment of early-stage NPC, which reflects the need to enhance protection of other salivary glands.
Related Papers (5)
A systematic review of salivary gland hypofunction and xerostomia induced by cancer therapies: prevalence, severity and impact on quality of life
Siri Beier Jensen,Anne Marie Lynge Pedersen,Arjan Vissink,Elo Andersen,C. G. Brown,Andrew Davies,J. Dutilh,Janet S. Fulton,Ljiljana Janković,Nilza Nelly Fontana Lopes,A. L. S. Mello,L. V. Muniz,C. A. Murdoch-Kinch,Raj G. Nair,Joel J. Napeñas,A. Nogueira-Rodrigues,Deborah P. Saunders,B. Stirling,I. von Bültzingslöwen,Dianna Weikel,Linda S. Elting,Frederik Spijkervet,Michael T. Brennan +22 more
Parotid-sparing intensity modulated versus conventional radiotherapy in head and neck cancer (PARSPORT): a phase 3 multicentre randomised controlled trial.
Christopher M. Nutting,Christopher M. Nutting,James P Morden,Kevin J. Harrington,Kevin J. Harrington,Teresa Guerrero Urbano,Shreerang Bhide,Catharine H. Clark,Elizabeth Miles,Aisha Miah,Kate Newbold,Mary Anne Lagmay Tanay,Fawzi Adab,Sarah Jefferies,Christopher D Scrase,Beng K. Yap,Roger A'Hern,M. Sydenham,M. Emson,Emma Hall +19 more